Welcome to our dedicated page for Vita Coco Company SEC filings (Ticker: COCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vita Coco Company, Inc.'s SEC filings document financial results, operating updates, governance matters, and public-company disclosures for its beverage brand portfolio. Form 8-K reports include quarterly and annual results, guidance updates, Regulation FD disclosures, and other material events related to the company’s coconut water and better-for-you beverage operations.
Proxy materials describe annual meeting proposals, board structure, committee assignments, executive compensation, equity awards, and stockholder voting matters. Additional 8-K filings record director appointments, board retirements, officer roles, compensation arrangements, tariff-related disclosures, and the company’s capital-market reporting obligations as a Nasdaq-listed Delaware corporation.
Vita Coco Company, Inc. (COCO) reported an insider transaction by Executive Chairman and Director Michael Kirban. On 11/14/2025, a Rule 10b5-1 trading plan sale of 5,102 shares of common stock was executed at $44 per share. After this trade, Kirban beneficially owns 127,629 shares directly, 1,479,049 shares indirectly through the Michael Kirban 2010 Trust, and 615,681 shares indirectly through the Michael Kirban Revocable Trust.
Kirban also holds several non-qualified stock options, including 546,000 options with a $10.178 exercise price expiring 12/16/2029 and other grants with exercise prices ranging from $15 to $32.78 and expirations through 03/03/2035. Some options are fully vested and currently exercisable, while others vest in four equal annual installments starting on specified dates.
Vita Coco Company, Inc. (COCO) reported an insider transaction by a director. On 11/14/2025, the reporting person exercised a non-qualified stock option to acquire 10,000 shares of common stock at an exercise price of $10.178 per share and then sold 10,000 shares at a weighted average price of $43.7226 per share under a Rule 10b5-1 trading plan. Following these transactions, the reporting person beneficially owned 12,162 shares of common stock directly and held 20,675 stock options, which are fully vested and currently exercisable, with an expiration date of 12/16/2029.
The Vita Coco Company, Inc. filed a current report to let investors know it has issued a press release about tariff relief affecting the business. The company used this filing under Regulation FD, which is designed to share important information with all investors at the same time. The press release, dated November 17, 2025, is attached as an exhibit and incorporated by reference. The disclosure is being furnished rather than filed, meaning it does not carry certain legal liabilities that formal financial statements do.
Vita Coco Company, Inc. (COCO) director Ira Liran reported open‑market sales of company stock executed under a Rule 10b5‑1 trading plan. On 11/05/2025, he sold a total of 50,000 shares in two tranches: 20,000 shares at a weighted‑average price of $41.404 and 30,000 shares at a weighted‑average price of $41.407. The sales were completed across multiple transactions within the disclosed price range.
Following these transactions, Liran beneficially owns 538,341 shares directly and 662,579 shares indirectly through the Ira Liran 2012 Family Trust.
Vita Coco (COCO) reported an insider transaction by its Chief Marketing Officer, Jane Prior. On 10/29/2025, she exercised 10,000 stock options at $10.178 per share and, on the same day, sold 10,000 shares at an average price of $45.242. The sales were made pursuant to a Rule 10b5-1 trading plan.
Following these transactions, she beneficially owns 123,666 shares directly. The filing also lists multiple outstanding non‑qualified stock option grants with various exercise prices and expiration dates.
Vita Coco Company, Inc. (COCO) director Ira Liran reported the sale of 40,000 shares of common stock on 10/29/2025 under a Rule 10b5-1 trading plan. The weighted average sale price was $45.577, with individual transactions ranging from $44.07 to $48.00.
Following the transactions, Liran held 558,341 shares directly and 692,579 shares indirectly through the Ira Liran 2012 Family Trust.
Vita Coco (COCO) Executive Chairman and Director Michael Kirban reported open‑market sales made under a Rule 10b5‑1 trading plan. He sold 30,000 shares at $45.701 on 10/29/2025 and 14,898 shares at a weighted average price of $44.211 on 10/30/2025.
The 10/30 transactions occurred in multiple trades between $44.00 and $45.00. Following the reported sales, beneficial ownership reported included 1,484,151 shares held indirectly by the Michael Kirban 2010 Trust, plus 127,629 shares held directly and 615,681 shares held indirectly by the Michael Kirban Revocable Trust.
Reported derivative holdings include non‑qualified stock options to purchase 546,000 shares at $10.178 expiring 12/16/2029 (fully vested), 298,507 shares at $15 expiring 10/21/2031, and 70,715 shares at $32.78 expiring 03/03/2035, among others, with specified vesting schedules.
Vita Coco (COCO) reported insider activity by Chief Operating Officer Jonathan Burth. On 10/29/2025, he exercised stock options at $10.178 per share for 2,334 and 20,000 shares (code M), then sold the same amounts (code S) at weighted average prices of $47.948 and $45.711, respectively, pursuant to a Rule 10b5-1 trading plan.
Following these transactions, Burth directly beneficially owned 76,127 shares of common stock. The filing also lists multiple outstanding non-qualified stock options with stated exercise prices and expirations, including grants expiring between 2029 and 2035, with various vesting schedules as disclosed.
Vita Coco (COCO) CEO and Director Martin Roper filed a Form 4 reporting open-market sales of common stock on 10/29/2025 and 10/30/2025 made under a Rule 10b5-1 trading plan.
Direct transactions included 5,000 shares at a weighted average price of $46.087 on 10/29 and 500 shares at $45.00 on 10/30. Indirect transactions included 5,000 shares at a weighted average $46.108 on 10/29 and 500 shares at $45.00 on 10/30 by the Christopher G. Roper Exempt Family Trust, plus 5,000 shares each on 10/29 by the Peter S. Roper and Thomas L. Roper Exempt Family Trusts at weighted average prices within the disclosed ranges.
Following these transactions, reported beneficial holdings were 281,562 shares (direct), 215,631 (Christopher G. Roper Exempt Family Trust), 216,131 (Peter S. Roper Exempt Family Trust), 216,131 (Thomas L. Roper Exempt Family Trust), and 61,200 (by spouse).
The Vita Coco Company (COCO) reported higher Q3 2025 results. Net sales were $182.3 million versus $132.9 million a year ago, with gross profit of $68.7 million versus $51.6 million. Income from operations rose to $27.9 million from $20.6 million, and net income was $24.0 million versus $19.3 million. Diluted EPS was $0.40 compared with $0.32. For the nine months, net sales reached $482.0 million and net income was $65.8 million, with diluted EPS of $1.10.
Cash and cash equivalents were $203.7 million as of September 30, 2025. The company had no borrowings and $60.0 million available under its amended revolving credit facility, now maturing in 2030. Two customers accounted for 45% of year-to-date net sales. The board expanded the share repurchase authorization to $65.0 million; year-to-date repurchases totaled 338,416 shares for $10.2 million, leaving $42.0 million authorized. Management highlighted U.S. tariffs, citing a current blended rate of about 23% based on quarter-end sourcing, with review scheduled in November 2025.